Clinical trial · Interventional
Contribution of New Pancreatic MRI Sequences for the Evaluation of Tumor Response in Pancreatic Adenocarcinomas
NCT06842303CI-TRIAL-00092252PADMErecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pancreatic adenocarcinoma is the most pessimistic digestive cancer in terms of prognosis. Tumor response assessment is crucial, and the recent development of new magnetic resonance imaging sequences, such as high resolution applied to diffusion sequences (Harder et al., 2022) or magnetic resonance elastography (MRE) (Steinkohl et al., 2021), could help address this issue.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreas Adenocarcinomas | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| High-resolution diffusion sequence in MRI | Device | — | UNRESOLVED |
| Magnetic resonance elastography (MRE). | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Patient with a resectable pancreatic lesion
- description
- Pancreatic resection surgery
- interventionNames
- Device: Magnetic resonance elastography (MRE).
- Device: High-resolution diffusion sequence in MRI
- type
- EXPERIMENTAL
- label
- Patient with a borderline pancreatic lesion
- description
- Potential pancreatic resection surgery after chemotherapy.
- interventionNames
- Device: Magnetic resonance elastography (MRE).
- Device: High-resolution diffusion sequence in MRI
- type
- EXPERIMENTAL
- label
- Patient with locally advanced pancreatic lesion.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * CT scan diagnosis of non-metastatic pancreatic cancer on contrast-enhanced thoraco-abdomino-pelvic CT; * Adult patient: age ≥ 18 years; * Patient affiliated with a social security system or beneficiary of such a system; * Patient who has received complete information about the research organization and has signed an informed consent form. Exclusion Criteria: * Patient with a contraindication to MRI. * Person referred to in Articles L. 1121-5, L. 1121-7, and L. 1121-8 of the French Public Health Code. * Pregnant woman, parturient, or breastfeeding mother; * Minor (non-emancipated) individual; * Adult individual under legal protection (guardianship, curatorship, or judicial safeguard); * Adult individual unable to express consent. * Person deprived of liberty by a judicial or administrative decision, or person undergoing psychiatric care pursuant to Articles L. 32-12-1 and L. 3213-1 of the French Public Health Code.
References
Publications (0)
Data not yet available
No reference posted for this study.